# Cancer Center Administration

> **NIH NIH P30** · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2022 · $199,860

## Abstract

PROJECT ABSTRACT
Cancer is a large and growing problem among people living with HIV (PLWH). PLWH are far less likely to 
receive cancer treatment compared to uninfected counterparts. Even PLWH that receive cancer treatment 
experience worse cancer survival, suggesting that there are additional drivers of outcomes disparities. The 
disparity in cancer treatment and survival is especially concerning given the near normal life expectancy of 
PLWH in the era of antiretroviral therapy and the mortality burden faced by PLWH who develop cancer. 
Although PLWH experience more clinician-reported cancer treatment toxicity leading to early discontinuation of 
cancer treatment and hospital admission, little is known about the patient perspective of cancer treatment 
toxicity. Patient-reported outcomes (PROs) provide unique information on how delivered care affects patient 
health and well-being, and are predictors of poor cancer outcomes in the general cancer population. In Aim 1, 
we will assess the type, frequency, and severity of PROs for PLWH compared to cancer patients without HIV 
using the validated PROMIS to measure physical, mental, and social health for all cancer sites. We 
hypothesize that PLWH with cancer will experience more frequent and severe symptoms compared to HIVnegative cancer patients. In Aim 2, we will examine the relationship between PROs and cancer outcomes, 
including treatment completion, treatment delays, inpatient admission, cancer recurrence and survival. We 
hypothesize that higher patient-reported symptom burden will be associated with adverse treatment outcomes, 
particularly among PLWH. This retrospective study will identify disparities in cancer treatment toxicity for 
PLWH and HIV-negative cancer patients utilizing a validated PRO and measure associations between toxicity 
and real world clinical outcomes. Early identification and management of cancer treatment side effects will 
improve patient-centered, personalized and equitable cancer care for PLWH, thereby reducing cancer 
disparities and improving survival for this marginalized population.

## Key facts

- **NIH application ID:** 10690812
- **Project number:** 3P30CA042014-33S5
- **Recipient organization:** UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
- **Principal Investigator:** Scott Lloyd
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $199,860
- **Award type:** 3
- **Project period:** 1997-05-09 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10690812

## Citation

> US National Institutes of Health, RePORTER application 10690812, Cancer Center Administration (3P30CA042014-33S5). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10690812. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*